详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Development and therapeutic perspectives of CXCR4 antagonists for disease therapy

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Neurology, Laboratory of Neuro-system and Multimorbidity and State Key Laboratory of Biotherqpy and Cancer Center and Institute of Respiratory Health and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China [2]State Key Laboratory of Oral Diseases, National Cinical Research Center for Oral Diseases & Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China [3]Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongi University School of Medicine, Shanghai, 200433, China

出处：

DOI：

ISSN：

关键词： CXCR4 Antagonists HIV Cancer Drug design Structure-activity relationship

摘要：

Chemokine receptor 4 (CXCR4) is a subtype receptor protein of the GPCR family with a seven-transmembrane structure widely distributed in human tissues. CXCR4 is involved in diseases (e.g., HIV-1 infection), cancer proliferation and metastasis, inflammation signaling pathways, and leukemia, making it a promising drug target. Clinical trials on CXCR4 antagonists mainly focused on peptides and antibodies, with a few small molecule compounds, such as AMD11070 (2) and MSX-122 (3), showing promise in cancer treatment. This perspective discusses the structure-activity relationship (SAR) of CXCR4 and its role in diseases, mainly focusing on the SAR of CXCR4 antagonists. It also explores the standard structural features and target interactions of CXCR4 binding in different disease categories. Furthermore, it investigates various modification strategies to propose potential improvements in the effectiveness of CXCR4 drugs.Copyright © 2024 Elsevier Masson SAS. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区

医学

小类 | 1 区药物化学

最新[2023]版：

大类 | 2 区

医学

小类 | 1 区药物化学

第一作者：

第一作者机构： [1]Department of Neurology, Laboratory of Neuro-system and Multimorbidity and State Key Laboratory of Biotherqpy and Cancer Center and Institute of Respiratory Health and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]RIPK2 inhibitors for disease therapy: Current status and perspectives [2]Dual-target inhibitors based on COX-2: a review from medicinal chemistry perspectives [3]Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy [4]The high-resolution X-ray structure of vinca domain inhibitors of microtubules provides a rational approach for drug design. [5]Structure-Activity Relationship of Novel Pyrimidine Derivatives with Potent Inhibitory Activities against Mycobacterium tuberculosis [6]Recent discovery and development of AXL inhibitors as antitumor agents [7]Discovery of tetrahydrofuranyl spirooxindole-based SMYD3 inhibitors against gastric cancer via inducing lethal autophagy [8]Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer. [9]Structural and functional characteristics of pectins from three cultivars of apple (Malus pumila Mill.) pomaces [10]Cyclen-based lipidic oligomers as potential gene delivery vehicles.